‘Bio-Vision 2016’ Unveiled
『Bio‐Vision 2016』 is the second of National biotech promotion plans, relaying the 1994 plan which expires this year. 『Bio‐Vision 2016』, which will build upon the groundwork laid by the preceding plan, aims at “acquiring internationally‐competitive source technologies” and “expanding core infrastructure for technology industrialization”.
※ Phase I Plan for Catching Up ⇒ Phase II Plan for Leading
South Korea’s biotech fields have made remarkable progress over a relatively short period. Helped by the ten‐year government promotion plan, the country’s biotech industry has grown by leaps and bounds.
South Korea’s global ranking in number of papers appeared in SCIE‐listed publications rose from 29th in 1994 to 13th in 2005, and its position in technological strength indicators climbed from 21st in 1994‐1997 to 14th in 2002‐2005.
Meanwhile, the local biotech market grew 14‐fold over its size in 1994, and is populated by as many as 600 ventures. The country is already seeing the tangible fruits of its investment in basic science, with strings of new Korean biotech drugs hailed as breakthroughs worldwide.
To capitalize on these achievements under the first ten‐year plan, and with lessons from past projects in mind, 『Bio‐Vision 2016』 proposes a new vision for the forthcoming decade, formulated Healthy “life‐oriented society” and Prosperous “bio‐economy,” accompanied by strategies designed closely in line with industry environments at home and abroad. The goals set for the next ten‐year period are reaching 7th globally in number of research papers published and technology patents and KRW 60 trillion in market size.
A four‐pronged strategy has been developed toward these goals: ‘innovative restructuring of the national biotech promotion system,’ ‘expanding infrastructure for upgrading R&D,’ ‘accelerating growth and achieving globalization of the biotech industry,’ and ‘regulatory and legal overhaul and enhancement of public acceptance’, along with 14 core missions.
Detailed plans outline promotion strategies for five key biotech fields, including life sciences; healthcare and medicine; food, agriculture and livestock; industrial processes/environment and maritime industry; and bioconvergence industry.
As a high‐level project plan comprehensively overseeing biotech promotion plans implemented across sections of government, 『Bio‐Vision 2016』 includes directions for gaining broader public support and participation such as strengthening research ethics and life ethics guidelines and stepping up awareness and information efforts. The plan, furthermore, contains measures to ensure greater efficiency in inter‐government project coordination, such as the introduction of a meta‐evaluation system and improvement of the inter‐agency coordination system.
The focus and selectivity of the plan will be sharpened by directing support to strategic biotech fields such as post‐genome research, genome to life research and converged technology fields such as Bio‐IT and Bio‐NT. Meanwhile, measures planned to enhance the business environment for companies include the acceleration of industrialization of research results, expanding the pool of technology transfer organizations and increasing business funding sources.
On the front of human resources development, the plan contains initiatives to produce biotech workforces adapted to the changing industry environment, such as stepping up support toward post‐doc and other junior researchers, training research manpower specialized in patent analysis, marketing, life ethics, research ethics and globalization, and broadening women’s participation in workforces.
One noteworthy fact about 『Bio‐Vision 2016』 is that it is the first government policy plan of its kind to have been developed using policy quality management techniques. The process of policymaking was divided into the steps of development, publicizing, evaluation and feedback, and each of these stages was controlled for quality. Public opinion was surveyed through gender impact analysis, public discussions and hearings held nationwide, both in physical locations and over the internet, to identify potential gaps between basic research and industrialization and conflicts of interest between fields, sexes and regions, and find solutions to bridge and resolve them.
As part of the publicity effort for the new plan, a ‘name the plan’ contest was held. 『Bio‐Vision 2016』 was the title chosen among 495 total entries received. To contribute to the quality of the policy and broaden public participation in government policymaking, a 150‐member citizens’ committee, dubbed “Policy Quality Evaluation Corps,” was set up to assess the plan’s content and procedural appropriateness.
Biotech fields require attributes like patience, tenacity and detail‐orientedness, that are some of the chief national traits of the Korean people. Provided sound ethical standards in the research community and industry and public understanding and support, coupled with continued support from the government, biotechnology, the strongest and the most likely candidate to succeed IT as the prime engine of growth, can propel the Korean economy and make major contributions to the health and well‐being of people around the globe and the quality of their lives.
『Bio‐Vision 2016』 was jointly developed by 8 government agencies including the Ministry of Science and Technology (in chief charge) and the Ministry of Education and Human Resources Development, in accordance with the Biotechnology Promotion Act. A rolling plan is to be established every year.
연락처
Basic Research Bureau Fundamental Technology Development Division, Deputy Director, Yeon Kim 031) 436-8606/7
이 보도자료는 Ministry of Science & Technology가(이) 작성해 뉴스와이어 서비스를 통해 배포한 뉴스입니다.
-
2005년 10월 12일 16:39
-
2005년 9월 22일 17:32